Breaking News, Collaborations & Alliances

TC BioPharm and CareDx Partner to Advance AML Therapy Trial

Will support the ACHIEVE clinical trial using the AlloCell test for pharmacokinetic monitoring of allogenic cell therapy.

Author Image

By: Charlie Sternberg

Associate Editor

TC BioPharm PLC, a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, has partnered with CareDx Inc. to perform pharmacokinetic analysis using CareDx’s AlloCell solution in the ACHIEVE clinical trial.   The ACHIEVE clinical trial is an adaptive, open-label, phase II study designed to evaluate the efficacy and effectiveness of TCB008, an allogeneic gamma delta T cell therapy for patients with Acute Myeloid Leukemia ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters